This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kerber, M. Articles by Machein, M. R. Search for Related Content PubMed PubMed Citation Articles by Kerber, M. Articles by Machein, M. R.

Flt-1 Signaling in Macrophages Promotes Glioma Growth In vivo

¹ Tumor Angiogenesis Research Group, Department of Neurosurgery, University of Freiburg, Freiburg, Germany; ² Institute of Neurology, Edinger Institute, University of Frankfurt, Frankfurt, Germany; ³ Department of Medical Physics in Radiology, Junior Group Molecular Imaging, German Cancer Research Center, Heidelberg, Germany; ⁴ Department of Experimental Cardiology, Max-Planck Institute for Heart and Lung Research, Bad Nauheim, Germany; ⁵ Department of Cardiology and Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands; and ⁶ Department of Genetics, Institute of Medical Science, University of Tokyo, Tokyo, Japan

Requests for reprints: Marcia Machein, Department of Neurosurgery, Neurocenter, University of Freiburg, Breisacher Straβe 64, 79106 Freiburg, Germany. Phone: 49-761-2705147; Fax: 49-761-2705147; E-mail: Marcia.machein{at}uniklinik-freiburg.de.

Key Words: VEGF • VEGF Receptors • angiogenesis • glioma • macrophages

Several lines of evidence indicate that Flt-1, a fms-like tyrosine kinase receptor, which binds to vascular endothelial growth factor (VEGF)-A, VEGF-B, and PlGF, is a positive regulator of angiogenesis in the context of tumor growth and metastasis. However, the molecular basis of its action is still not clear. Besides endothelial cells, Flt-1 is also expressed by other different cell types, including myeloid hematopoeitic cells (monocytes and macrophages). To examine the functions of Flt-1 expressed by bone marrow–derived myeloid cells in supporting tumor growth and angiogenesis, Flt-1 tyrosine kinase–deficient (Flt-1 TK–/–) bone marrow cells were transplanted into lethally irradiated syngeneic recipients. After hematopoietic reconstitution, we orthotopically implanted syngeneic wild-type glioma cells or glioma cells overexpressing either VEGF₁₆₄ or PlGF-2. Loss of Flt-1 signaling in bone marrow–derived myeloid cells led to a significant decrease in tumor volume and vascularization in gliomas. VEGF but not PlGF overexpressed by glioma cells restored the tumor growth rate in Flt-1 TK–/– bone marrow chimera. VEGF and PlGF overexpression by tumor cells induced an accumulation of bone marrow–derived myeloid cells into tumor tissue. This infiltration was decreased in tumors grown in Flt-1 TK–/– bone marrow chimeras. When investigating chemokines and growth factors involved in myeloid cell recruitment, we determined elevated SDF-1/CXCL12 levels in VEGF- and PlGF-overexpressing tumors. Collectively, these results suggest that Flt-1 signaling in myeloid cells is essential to amplify the angiogenic response and to promote glioma growth. [Cancer Res 2008;68(18):7342–51]

This article has been cited by other articles:

				Y. Kubota, K. Takubo, T. Shimizu, H. Ohno, K. Kishi, M. Shibuya, H. Saya, and T. Suda M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis J. Exp. Med., May 11, 2009; 206(5): 1089 - 1102. [Abstract] [Full Text] [PDF]

				Y. Cao Positive and Negative Modulation of Angiogenesis by VEGFR1 Ligands Sci. Signal., February 24, 2009; 2(59): re1 - re1. [Abstract] [Full Text] [PDF]